I'm LongbridgeAI, I can summarize articles.U.S. stock futures rose, but several major stocks declined in pre-market trading. Novo Nordisk fell 4.8% following disappointing Phase 3 trial results for Cagrisema. Other significant drops included Aligos Therapeutics (-15.1%), Telix Pharmaceuticals (-7.9%) amid merger news, Perspective Therapeutics (-7.3%), Stewards Inc (-7%), Li Auto (-3.5%), New Pacific Metals (-3.3%), and Inventiva SA (-2.7%).
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 1% on Monday.
Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply in pre-market trading after the company released topline results from Phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly Cagrisema (Cagrilintide and Semaglutide).
Novo Nordisk shares dipped 4.8% to $41.15 in pre-market trading.
Here are some other stocks moving lower in pre-market trading.
- Aligos Therapeutics Inc (NASDAQ:ALGS) fell 15.1% to $4.45 in pre-market trading.
- Telix Pharmaceuticals (NASDAQ:TLX) fell 7.9% to $11.60 in pre-market trading. Telix Pharmaceuticals signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE.
- Perspective Therapeutics Inc (NYSE:CATX) fell 7.3% to $2.67 in pre-market trading.
- Stewards Inc (NASDAQ:SWRD) declined 7% to $2.00 in pre-market trading.
- Li Auto Inc (NASDAQ:LI) fell 3.5% to $11.72 in pre-market trading. Li Auto, last week, announced the launch of its flagship Li i9 SUV, priced at RMB369,800 for its standard configuration.
- New Pacific Metals Corp (NYSE:NEWP) fell 3.3% to $5.80 in pre-market trading.
- Inventiva SA – ADR (NASDAQ:IVA) declined 2.7% to $3.68 in pre-market trading.
Photo via Shutterstock